AU2017374459B2 - Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome - Google Patents

Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome Download PDF

Info

Publication number
AU2017374459B2
AU2017374459B2 AU2017374459A AU2017374459A AU2017374459B2 AU 2017374459 B2 AU2017374459 B2 AU 2017374459B2 AU 2017374459 A AU2017374459 A AU 2017374459A AU 2017374459 A AU2017374459 A AU 2017374459A AU 2017374459 B2 AU2017374459 B2 AU 2017374459B2
Authority
AU
Australia
Prior art keywords
tremor
syndrome
formula
group
essential
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017374459A
Other languages
English (en)
Other versions
AU2017374459A1 (en
Inventor
Hye Sung Lee
Han Ju Yi
Jin Uk Yoo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Publication of AU2017374459A1 publication Critical patent/AU2017374459A1/en
Application granted granted Critical
Publication of AU2017374459B2 publication Critical patent/AU2017374459B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2017374459A 2016-12-14 2017-12-14 Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome Active AU2017374459B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160170225 2016-12-14
KR10-2016-0170225 2016-12-14
PCT/KR2017/014743 WO2018111009A1 (ko) 2016-12-14 2017-12-14 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Publications (2)

Publication Number Publication Date
AU2017374459A1 AU2017374459A1 (en) 2019-07-04
AU2017374459B2 true AU2017374459B2 (en) 2023-04-27

Family

ID=62558966

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017374459A Active AU2017374459B2 (en) 2016-12-14 2017-12-14 Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome

Country Status (14)

Country Link
US (1) US11033531B2 (enExample)
EP (1) EP3556364B1 (enExample)
JP (1) JP7086076B2 (enExample)
KR (1) KR102635941B1 (enExample)
CN (1) CN110267657B (enExample)
AU (1) AU2017374459B2 (enExample)
CA (1) CA3046300A1 (enExample)
CL (1) CL2019001623A1 (enExample)
ES (1) ES3039979T3 (enExample)
IL (1) IL267191B2 (enExample)
MX (1) MX391363B (enExample)
MY (1) MY198417A (enExample)
WO (1) WO2018111009A1 (enExample)
ZA (1) ZA201903749B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019098626A1 (ko) * 2017-11-14 2019-05-23 에스케이바이오팜 주식회사 후기 나트륨 전류의 증가와 관련된 질환을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
JP7408643B2 (ja) * 2018-09-21 2024-01-05 エスケー バイオファーマスティカルズ カンパニー リミテッド カルバメート化合物及びそれを含む製剤の急性ストレス障害又は心的外傷後ストレス障害の予防、軽減又は治療のための使用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067926A1 (en) * 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating movement disorders
WO2006112685A1 (en) * 2005-04-22 2006-10-26 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
WO2014142518A1 (en) * 2013-03-12 2014-09-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating a movement disorder
WO2017200318A1 (ko) * 2016-05-19 2017-11-23 에스케이바이오팜 주식회사 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530694A (ja) 2004-03-29 2007-11-01 メルク エンド カムパニー インコーポレーテッド ナトリウムチャネル遮断薬としてのビアリール置換ピラジノン
CN101657194B (zh) * 2007-03-05 2013-10-23 Indus生物技术私人有限公司 包含葫芦巴碱和4-羟基异亮氨酸的药物组合物及其方法
CN102803233B (zh) * 2009-06-22 2017-03-01 爱思开生物制药株式会社 制备氨基甲酸(r)‑1‑芳基‑2‑四唑基‑乙酯的方法
US8404461B2 (en) * 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067926A1 (en) * 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating movement disorders
WO2006112685A1 (en) * 2005-04-22 2006-10-26 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
WO2014142518A1 (en) * 2013-03-12 2014-09-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating a movement disorder
WO2017200318A1 (ko) * 2016-05-19 2017-11-23 에스케이바이오팜 주식회사 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Also Published As

Publication number Publication date
MX391363B (es) 2025-03-21
IL267191A (enExample) 2019-07-31
MX2019006941A (es) 2019-09-06
WO2018111009A1 (ko) 2018-06-21
JP7086076B2 (ja) 2022-06-17
ZA201903749B (en) 2022-01-26
CA3046300A1 (en) 2018-06-21
CN110267657A (zh) 2019-09-20
RU2019121914A3 (enExample) 2021-04-21
IL267191B2 (en) 2023-05-01
KR102635941B1 (ko) 2024-02-13
KR20190087573A (ko) 2019-07-24
EP3556364A4 (en) 2020-06-17
US20190336481A1 (en) 2019-11-07
JP2020502137A (ja) 2020-01-23
AU2017374459A1 (en) 2019-07-04
CL2019001623A1 (es) 2019-08-23
MY198417A (en) 2023-08-29
US11033531B2 (en) 2021-06-15
RU2019121914A (ru) 2021-01-15
CN110267657B (zh) 2022-12-13
EP3556364B1 (en) 2025-08-27
ES3039979T3 (en) 2025-10-28
IL267191B1 (en) 2023-01-01
EP3556364A1 (en) 2019-10-23
BR112019012000A2 (pt) 2019-10-29

Similar Documents

Publication Publication Date Title
AU2017374459B2 (en) Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome
JP7578747B2 (ja) 欠神発作又は欠神発作を示すてんかんの予防、軽減又は治療のためのカルバメート化合物の使用
AU2017374458B2 (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
KR102693607B1 (ko) 하지 불안 증후군을 치료하기 위한 치료제
RU2776368C2 (ru) Применение карбаматного соединения для профилактики, облегчения или лечения треморов или синдрома тремора
HK40015061A (en) Use of carbamate compounds for preventing, alleviating, or treating tremors or tremor syndrome
HK40015061B (en) Use of carbamate compounds for preventing, alleviating, or treating tremors or tremor syndrome
BR112019012000B1 (pt) Uso de um composto de carbamato
EP3556363B1 (en) Use of carbamate compound for prevention, alleviation or treatment of pruritus
US20220117941A1 (en) Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
RU2787771C2 (ru) Применение карбаматного производного для предотвращения, облегчения или лечения малого эпилептического припадка или эпилепсии, проявляющей малый эпилептический припадок
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)